AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
ProMIS Neurosciences Receives DSMB Approval for PMN310 Alzheimer's Trial to Advance to Final Dose Cohort.
ByAinvest
Wednesday, Sep 3, 2025 7:01 am ET1min read
ProMIS Neurosciences has received DSMB approval to advance to the final dose escalation cohort in its Phase 1b Alzheimer's trial of PMN310. The trial remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026. No cases of amyloid-related imaging abnormalities (ARIA) have been observed to date. Enrollment of patients into the third and final dose escalation cohort is now underway.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet